The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

In recent years, the U.K.-listed pharma giant has called increasingly on U.S. law firms for its transactional work.

UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...

With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...

May 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs. The Indian unit ...

Net Sales at Rs 966.08 crore in March 2025 up 6.06% from Rs. 910.87 crore in March 2024. Quarterly Net Profit at Rs. 260.14 ...

Todays focus will be on GSK Pharma shares in light of the companys announced topline growth and profitability for the full ...

The company registered standalone net profits after tax of EGP 43.559 million in Q1 2025, compared to EGP 2.046 million in net losses during Q1 2024 ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...